Related references
Note: Only part of the references are listed.RNA-seq Reveals Aurora Kinase-Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma
Sumanta K. Pal et al.
MOLECULAR CANCER RESEARCH (2015)
Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
Christos E. Kyriakopoulos et al.
Clinical Genitourinary Cancer (2014)
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
M. H. Voss et al.
ANNALS OF ONCOLOGY (2014)
Sarcomatoid Dedifferentiation in Metastatic Clear Cell Renal Cell Carcinoma and Outcome on Treatment With Anti-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Retrospective Analysis
Benoit Beuselinck et al.
CLINICAL GENITOURINARY CANCER (2014)
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
M. D. Michaelson et al.
BRITISH JOURNAL OF CANCER (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802
Naomi B. Haas et al.
MEDICAL ONCOLOGY (2012)
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Nikhil Wagle et al.
CANCER DISCOVERY (2012)
Sarcomatoid-variant Renal Cell Carcinoma Treatment Outcome and Survival in Advanced Disease
Ana M. Molina et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2011)
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre
Eric Jonasch et al.
BJU INTERNATIONAL (2011)
Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far
Patricia A. Tang et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2011)
Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
Janice P. Dutcher et al.
MEDICAL ONCOLOGY (2011)
Combination of Gemcitabine and Doxorubicin in Rapidly Progressive Metastatic Renal Cell Carcinoma and/or Sarcomatoid Renal Cell Carcinoma
G. Roubaud et al.
ONCOLOGY (2011)
Expression of hypoxia inducible factor-1α and 2α in conventional renal cell carcinoma with or without sarcomatoid differentiation
Ja Hyeon Ku et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2011)
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
Dora Dias-Santagata et al.
EMBO MOLECULAR MEDICINE (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dose-finding Trial of a Combined Regimen With Bevacizumab, Immunotherapy, and Chemotherapy in Patients With Metastatic Renal Cell Cancer: An Italian Oncology Group for Clinical Research (GOIRC) Study
Sebastiano Buti et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)
Joaquim Bellmunt et al.
LANCET ONCOLOGY (2010)
Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy
Ali Reza Golshayan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
DM Nanus et al.
CANCER (2004)
Sarcomatoid differentiation in renal cell carcinoma - A study of 101 cases
M de Peralta-Venturina et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2001)
Share Paper
